PBM MAC Lists Reimburse Pharmacies Below Drug Acquisition Cost

PBMs maintain proprietary Maximum Allowable Cost (MAC) lists that set the maximum reimbursement a pharmacy receives for dispensing a generic drug. These lists are updated at the PBM's discretion and often do not reflect current market acquisition costs. When a drug experiences a supply shortage or price increase, the pharmacy's acquisition cost rises immediately, but the PBM's MAC reimbursement may not be updated for weeks or months. The pharmacy is forced to dispense the drug at a loss or refuse to fill the prescription. This is not an edge case — it happens on a significant percentage of generic prescriptions. A 2023 NCPA survey found that 90% of independent pharmacies reported being reimbursed below acquisition cost on at least some prescriptions every month, with an average of 15-20% of generic claims reimbursed below cost. For a pharmacy filling 300 prescriptions per day, that means 45-60 prescriptions daily are filled at a loss. The pharmacy must absorb these losses because refusing to fill creates patient access problems and risks PBM network termination. The cumulative effect is financial strangulation of independent pharmacies. Average independent pharmacy margins have declined from 22% in 2010 to under 2% in 2023 according to NCPA data. When margins are this thin, a single bad month of underwater MAC reimbursements can push a pharmacy into insolvency. Pharmacies cannot simply stop filling underwater prescriptions because patients need their medications, and the pharmacy's contract requires them to fill prescriptions for network patients. MAC pricing abuse persists because the lists are entirely proprietary. Each PBM maintains its own MAC list, updated on its own schedule, with no regulatory requirement to tie reimbursement to actual acquisition cost. The pharmacy signs a contract agreeing to accept MAC pricing but has no visibility into how the MAC is calculated or when it will be updated. Some states have passed MAC transparency laws requiring PBMs to update lists within a set timeframe and provide appeals processes, but enforcement is inconsistent. The structural problem is that the PBM has complete information about both the acquisition cost (through wholesale purchasing data) and the reimbursement rate (which it sets), while the pharmacy sees only its own acquisition cost and the PBM's take-it-or-leave-it reimbursement. This information asymmetry, combined with the pharmacy's inability to walk away from a major PBM network without losing most of its patients, creates a textbook monopsony exploitation scenario.